TY - JOUR
T1 - Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells
AU - Yin, Jun
AU - Hashimoto, Ayako
AU - Izawa, Mineko
AU - Miyazaki, Keiko
AU - Chen, Guo Yun
AU - Takematsu, Hiromu
AU - Kozutsumi, Yasunori
AU - Suzuki, Akemi
AU - Furuhata, Kimio
AU - Cheng, Feng Leng
AU - Lin, Chun Hung
AU - Sato, Chihiro
AU - Kitajima, Ken
AU - Kannagi, Reiji
PY - 2006/3/15
Y1 - 2006/3/15
N2 - Tumor hypoxia figures heavily in malignant progression by altering the intracellular glucose metabolism and inducing angiogenic factor production, thus, selecting and expanding more aggressive cancer cell clones. Little is known, however, regarding hypoxia-induced antigenic changes in cancers. We investigated the expression of N-glycolyl sialic acid (NeuGc)-GM2, a cancer-associated ganglioside containing non-human sialic acid, NeuGc, in human cancers. Cancer tissues prepared from patients with colon cancers frequently expressed NeuGc-GM2, whereas it was virtually absent in nonmalignant colonic epithelia. Studies on cultured cancer cells indicated that the non-human sialic acid was incorporated from culture medium. Hypoxic culture markedly induced mRNA for a sialic acid transporter, sialin, and this accompanied enhanced incorporation of NeuGc as well as N-acetyl sialic acid. Transfection of cells with sialin gene conferred accelerated sialic acid transport and induced cell surface expression of NeuGc-GM2. We propose that the preferential expression of NeuGc-GM2 in cancers is closely associated with tumor hypoxia. Hypoxic culture of tumor cells induces expression of the sialic acid transporter, and enhances the incorporation of non-human sialic acid from the external milieu. A consequence of this is the acquisition of cancer-associated cell surface gangliosides, typically GM2, containing non-human sialic acid (NeuGc), which is not endogenously synthesized through CMP-N-acetyl sialic acid hydroxylase because humans lack the gene for the synthetic enzyme. As hypoxia is associated with diminished response to radiotherapy and chemotherapy, NeuGc-GM2 is a potential therapeutic target for hypoxic cancer cells.
AB - Tumor hypoxia figures heavily in malignant progression by altering the intracellular glucose metabolism and inducing angiogenic factor production, thus, selecting and expanding more aggressive cancer cell clones. Little is known, however, regarding hypoxia-induced antigenic changes in cancers. We investigated the expression of N-glycolyl sialic acid (NeuGc)-GM2, a cancer-associated ganglioside containing non-human sialic acid, NeuGc, in human cancers. Cancer tissues prepared from patients with colon cancers frequently expressed NeuGc-GM2, whereas it was virtually absent in nonmalignant colonic epithelia. Studies on cultured cancer cells indicated that the non-human sialic acid was incorporated from culture medium. Hypoxic culture markedly induced mRNA for a sialic acid transporter, sialin, and this accompanied enhanced incorporation of NeuGc as well as N-acetyl sialic acid. Transfection of cells with sialin gene conferred accelerated sialic acid transport and induced cell surface expression of NeuGc-GM2. We propose that the preferential expression of NeuGc-GM2 in cancers is closely associated with tumor hypoxia. Hypoxic culture of tumor cells induces expression of the sialic acid transporter, and enhances the incorporation of non-human sialic acid from the external milieu. A consequence of this is the acquisition of cancer-associated cell surface gangliosides, typically GM2, containing non-human sialic acid (NeuGc), which is not endogenously synthesized through CMP-N-acetyl sialic acid hydroxylase because humans lack the gene for the synthetic enzyme. As hypoxia is associated with diminished response to radiotherapy and chemotherapy, NeuGc-GM2 is a potential therapeutic target for hypoxic cancer cells.
UR - http://www.scopus.com/inward/record.url?scp=33645532616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645532616&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-05-2615
DO - 10.1158/0008-5472.CAN-05-2615
M3 - Article
C2 - 16540641
AN - SCOPUS:33645532616
SN - 0008-5472
VL - 66
SP - 2937
EP - 2945
JO - Cancer Research
JF - Cancer Research
IS - 6
ER -